- Home
- AEYE vs MCRB Comparison
AEYE vs MCRB Comparison
Compare AEYE & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEYE
- MCRB
- Stock Information
- Founded
- AEYE 2005
- MCRB 2010
- Country
- AEYE United States
- MCRB United States
- Employees
- AEYE N/A
- MCRB N/A
- Industry
- AEYE Computer Software: Prepackaged Software
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- AEYE Technology
- MCRB Health Care
- Exchange
- AEYE Nasdaq
- MCRB Nasdaq
- Market Cap
- AEYE 164.9M
- MCRB 144.6M
- IPO Year
- AEYE N/A
- MCRB 2015
- Fundamental
- Price
- AEYE $13.00
- MCRB $18.91
- Analyst Decision
- AEYE Strong Buy
- MCRB Hold
- Analyst Count
- AEYE 4
- MCRB 4
- Target Price
- AEYE $25.25
- MCRB $14.33
- AVG Volume (30 Days)
- AEYE 96.0K
- MCRB 123.5K
- Earning Date
- AEYE 11-06-2025
- MCRB 11-12-2025
- Dividend Yield
- AEYE N/A
- MCRB N/A
- EPS Growth
- AEYE N/A
- MCRB N/A
- EPS
- AEYE N/A
- MCRB 10.22
- Revenue
- AEYE $38,238,000.00
- MCRB N/A
- Revenue This Year
- AEYE $17.16
- MCRB N/A
- Revenue Next Year
- AEYE $14.79
- MCRB N/A
- P/E Ratio
- AEYE N/A
- MCRB $1.93
- Revenue Growth
- AEYE 18.53
- MCRB N/A
- 52 Week Low
- AEYE $8.91
- MCRB $6.53
- 52 Week High
- AEYE $34.85
- MCRB $24.67
- Technical
- Relative Strength Index (RSI)
- AEYE 42.16
- MCRB 49.93
- Support Level
- AEYE $13.57
- MCRB $18.54
- Resistance Level
- AEYE $14.50
- MCRB $21.50
- Average True Range (ATR)
- AEYE 0.75
- MCRB 1.29
- MACD
- AEYE -0.20
- MCRB -0.17
- Stochastic Oscillator
- AEYE 7.87
- MCRB 22.98
About AEYE AudioEye Inc.
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. Trusted by the ADP, Tommy Hilfiger, A360 Media, Samsung, Landry's and others. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.